Sartorius opens Cell Culture Technology Center in Ulm’s Science Park III at Eselsberg

19. November 2021

The life science company Sartorius has officially opened its Cell Culture Technology Centre in Ulm’s Science Park III at Eselsberg. Around 120 people work in the 6,000-square-metre building with laboratories for the development of cell lines and the optimisation of cell culture media used by manufacturers of biologics for the production of modern drugs and vaccines. Sartorius has invested a total of around 30 million euros in Ulm for this purpose. The Lord Mayor of Ulm, Gunter Czisch, and the President of the University of Ulm, Prof. Dr.-Ing. Michael Weber, also attended the opening ceremony on Thursday, which was held virtually due to the pandemic.

“The Cell Culture Technology Center gives us the opportunity to support the producers of biopharmaceuticals even more efficiently, so that innovative drugs reach patients faster. At the same time, it helps us to grow in a promising market. We will therefore continue to hire new employees in the future,” said Hugo de Wit, Head of Cell Culture Technologies at Sartorius and Managing Director of the Ulm site. At present, Sartorius has more than a dozen vacancies to fill in Ulm; worldwide, the number of vacancies is around 1,300. As a leading international partner to biopharmaceutical research and industry, Sartorius in Ulm develops cell lines and protein production processes, licenses technologies for the manufacture of proteins and offers cell culture media. The proteins produced by living cells are used in the development and production of biopharmaceutical drugs and vaccines.


Sartorius in brief
The Sartorius Group is a leading international partner to biopharmaceutical research and industry. The Lab Products & Services Division focuses on research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies and academic research institutions with innovative laboratory instruments and consumables. The Bioprocess Solutions division contributes to the safe and efficient production of biotech drugs and vaccines with a broad product portfolio focused on single-use solutions. The Group is growing at an average of double-digit rates per year and regularly supplements its portfolio with acquisitions of complementary technologies. In the 2020 financial year, the company achieved sales of around 2.34 billion euros. At the end of 2020, nearly 11,000 employees were working for customers around the globe at the Group’s approximately 60 production and sales locations. Follow Sartorius on Twitter and on LinkedIn.


Foto: Sartorius AG